Enamine (Ukraine) leads ALISE, another EU-funded project

Enamine Ltd (Ukraine) researchers lead another EU-funded Project ALISE (Anti-Cancer Light-Controllable Antibody-Peptide Conjugates), jointly with scientists from the National Cancer Institute of Ukraine, and partners from Germany, Latvia, The Netherlands and the UK

This project is funded within the “MSCA-RISE-2020 – Research and Innovation Staff Exchange” topic with € 745 200 and will run for four years starting on 1 March 2021. It aims at integrating the expertise, resources and knowledge of participating institutions focusing on design, synthesis and preclinical study of conjugates of monoclonal antibodies with peptides whose anti-cancer activity can be enhanced in tumors by irradiation with light (LC-APCs). The possibility to boost the anti-cancer activity only in tumors, multiplied by targeting cancer cells by antibodies will be a basis for innovative and safer therapeutic strategies. Seven organizations partnered to cooperate:

  • Cancer Center Amsterdam, The Netherlands
  • Enamine Ltd., Ukraine
  • Karlsruhe Institute of Technology (KIT), Germany
  • Latvian Institute of Organic Synthesis, Latvia
  • Lumobiotics GmbH, Germany
  • National Cancer Institute of Ukraine
  • The University of Cambridge, UK

This project expands successful collaboration network established by Prof. Igor Komarov at the Taras Shevchenko National University of Kyiv (see e.g. our previous news features on his Forster Award) with Prof. Anne S. Ulrich at the Karlsruhe Institute of Technology (KIT), their earlier MSCA RISE project “PELICO“, highlighted as a success story by the EU, as well as a recent ERC Starting Grant awarded to Dr.  Mykhailiuk, CSO of the Enamine.